Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive ...
Bristol Myers Squibb today announced the presentation of more than 95 data disclosures, including 27 oral presentations, across company-sponsored studies and external collaborations at the 67th ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback